Emergence of increased azithromycin resistance during unsuccessful treatment of neisseria gonorrhoeae infection with azithromycin (Portland, OR, 2011)

Sexually Transmitted Diseases

Volumn 39, Issue 11, 2012, Pages 877-879

  Soge, Olusegun O ^a   Harger, Doug ^b   Schafer, Sean ^b   Toevs, Kim ^c   Raisler, Kathie A ^c   Venator, Kathy ^c   Holmes, King K ^a   Kirkcaldy, Robert D ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b OREGON HEALTH AUTHORITY   (United States)

^c MULTNOMAH COUNTY HEALTH DEPARTMENT   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFPODOXIME; CEFTRIAXONE; CIPROFLOXACIN; PENICILLIN G; TETRACYCLINE;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL MUTATION; BACTERIUM CULTURE; BACTERIUM ISOLATE; CASE REPORT; DISEASE DURATION; DYSURIA; GONORRHEA; HUMAN; MALE; MALE HOMOSEXUAL; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; PENICILLIN ALLERGY; SENTINEL SURVEILLANCE; URINE CULTURE;

ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); DRUG RESISTANCE, BACTERIAL; GENOTYPE; GONORRHEA; GUIDELINE ADHERENCE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE; OREGON; UNITED STATES;

EID: 84867741264     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e3182685d2b     Document Type: Article

References (30)

1. Lewis DA. The gonococcus fights backVIs this time a knock out? Sex Transm Infect 2010; 86:415-421.
2. Handsfield HH, Dalu DA, Martin DH, et al. Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Sex Transm Dis 1994; 21:107-111. (Pubitemid 24127677)
3. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Morb Mortal Wkly Rep 2010; 59(RR-12):49-55.
4. Dillon JA, Li H, Sealy J, et al. Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from three Caribbean countries: Trinidad, Guyana, and St. Vincent. Sex Transm Dis 2001; 28:508-514. (Pubitemid 32852655)
5. Centers for Disease Control and Prevention. Neisseria gonorrhoae with reduced susceptibility to azithromycinVSan Diego County, California, 2009. MMWR Morb Mortal Wkly Rep 2011; 60:579-581.
6. Yuan LF, Yin YP, Dai XQ, et al. Resistance to azithromycin of Neisseria gonorrhoeae isolates from 2 cities in China. Sex Transm Dis 2011; 38:764-768.
7. Palmer HM, Young H, Winter A, et al. Emergence and spread of azithromycin-resistant Neisseria gonorrhoeae in Scotland. J Anti-microb Chemother 2008; 62:490-494.
8. Sosa J, Ramirez-Arcos S, Ruben M, et al. High percentages of resistance to tetracycline and penicillin and reduced susceptibility to azithromycin characterize the majority of strain types of Neisseria gonorrhoeae isolates in Cuba, 1995-1998. Sex Transm Dis 2003; 30:443-448. (Pubitemid 36605495)
9. Katz AR, Komeya AY, Soge OO, et al. Neisseria gonorrhoeae with high-level resistance to azithromycin: Case-report of the first isolate identified in the United States. Clin Infect Dis 2012; 54:841-843.
10. Ison CA, Hussey J, Sankar KN, et al. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill 2011; 16:pii: 19833.
11. Tapsall JW, Shultz TR, Limnios EA, et al. Failure of azithromycin therapy in gonorrhea and discorrelation with laboratory test parameters. Sex Transm Dis 1998; 25:505-508. (Pubitemid 28553604)
12. Steingrimsson O, Olafsson JH, Thorarinsson H, et al. Azithromycin in the treatment of sexually transmitted disease. J Antimicrob Che-mother 1990; 25(suppl A):109-114. (Pubitemid 20043956)
13. Young H, Moyes A, McMillan A. Azithromycin and erythromycin resistant Neisseria gonorrhoeae following treatment with azithro-mycin. Int J STD AIDS 1997; 8:299-302. (Pubitemid 27202413)
14. Centers for Disease Control and Prevention. Gonococcal isolate surveillance project protocol. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2010. Available at: http://www.cdc.gov/std/gisp/GISP-Protocol07-15-2010.pdf. Accessed June 25, 2012.
15. Unemo M, Berglund T, OlcEn P, et al. Pulsed-field gel electropho-resis as an epidemiologic tool for Neisseria gonorrhoeae: Identification of clusters within serovars. Sex Transm Dis 2002; 29:25-31. (Pubitemid 34074428)
16. Martin IM, Ison CA, Aanensen DM, et al. Rapid sequence-based identification of gonococcal transmission clusters in a large metropolitan area. J Infect Dis 2004; 189:1497-1505. (Pubitemid 38552358)
17. Ng LK, Martin I, Liu G, et al. Mutation in 23S rRNA associated with macrolide resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 2002; 46:3020-3025.
18. Mavroidi A, Tzouvelekis LS, Kyriakis KP, et al. Multidrug-resistant strains of Neisseria gonorrhoeae in Greece. Antimicrob Agents Chemother 2001; 45:2651-2654. (Pubitemid 32801927)
19. Hagman KE, Pan W, Spratt BG, et al. Resistance of Neisseria gonorrhoeae to antimicrobial hydrophobic agents is modulated by the mtrRCDE efflux system. Microbiology 1995; 141:611-622.
20. Galarza PG, Abad R, Canigia LF, et al. New mutation in 23S rRNA gene associated with high level of azithromycin resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 2010; 54:1652-1653.
21. Chisholm SA, Dave J, Ison CA. High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. Antimicrob Agents Chemother 2010; 54:3812-3816.
22. Warner DM, Shafer WM, Jerse AE. Clinically relevant mutations that cause derepression of the Neisseria gonorrhoeae MtrC-MtrD-MtrE Efflux pump system confer different levels of antimicrobial resistance and in vivo fitness. Mol Microbiol 2008; 70:462-478.
23. Tapsall JW, Ndowa F, Lewis DA, et al. Meeting the public health challenge of multidrug-and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009; 7:821-834.
24. Brown ST, Pedersen HB, Holmes KK. Comparison of erythromy-cin base and estolate in gonococcal urethritis. JAMA 1977; 238:1371-1373. (Pubitemid 8189213)
25. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2010. Atlanta, GA: US Department of Health and Human Services, 2011.
26. Unemo M, Golparian D, Syversen G, et al. Two cases of verified clinical failures using internationally recommended first-line cefix-ime for gonorrhoea treatment, Norway, 2010. Euro Surveill 2010; 15:pii: 19721.
27. Unemo M, Golparian D, Stary A, et al. First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Euro Surveill 2011; 16:pii:19998.
28. Centers for Disease Control and Prevention. Cephalosporin susceptibility among Neisseria gonorrhoeae isolatesVUnited States, 2000-2010. MMWR Morb Mortal Wkly Rep 2011; 60:873-877.
29. Centers for Disease Control and Prevention (CDC). Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral Cephalosporins No Longer a Recommended Treatment for Gono-coccal Infections. MMWR Morb Mortal Wkly Rep 2012; 61:590-594.
30. Idsøe O, Guthe T, Willcon RR, et al. Nature and extent of penicillin side-reaction, with particular reference to fatalities from anaphylac-tic shock. Bull World Health Org 1968; 38:159-188.